Titan Medical Issues Corporate Update

Rhea-AI Summary

Titan Medical Inc. (TMD, TMDI) has announced a corporate update during the H.C. Wainwright Global Life Sciences Conference, highlighting its Enos™ robotic single access surgical system. The system aims to reduce trauma and enhance recovery in gynecologic surgeries, tapping into a potential $18 billion U.S. surgical robotics market. Titan's strong cash position of approximately $65.5 million supports its aggressive development timeline, with plans for a clinical study in 2022 and expected additional license revenue of $21 million in 2021 from its partnership with Medtronic.

Positive

• Titan Medical reported a pro forma cash position of approximately $65.5 million as of January 31, 2021.
• Generated $20 million in license revenue from deals with Medtronic in 2020.
• Plans to generate an additional $21 million in license revenue in 2021.
• The Enos surgical system addresses the underpenetrated surgical robotics market, particularly for gynecologic surgery.

Negative

• None.

Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD) (Nasdaq: TMDI), a medical device company focused on the design and development of surgical technologies for robotic single access surgery, today announced a corporate update in conjunction with its presentation at the H.C. Wainwright Global Life Sciences Conference. David McNally, President, CEO and Chairman of Titan Medical, will provide an overview of the Company and its Enos™ robotic single access surgical system at the conference, which is available for on-demand access on Titan Medical’s website under the “Investors” section.

“We are pleased to further detail our corporate strategy and the market opportunity for our Enos surgical system. The achievements to date position Titan for success in attaining our vision for robotic-assisted surgery that may allow patients less trauma, shorter hospitalization time, less scarring, faster recovery times and reduced post-operative pain,” said David McNally. “With a strong cash position and expert in-house technical talent, the advanced development of the Enos surgical system is at full intensity. We plan to continue executing on our corporate milestones with the objectives of completing product development in 2021 and human clinical studies in 2022.”

Corporate highlights, including those found in the presentation are included below.

Market Opportunity:

• Based on independent research, the total addressable US surgical robotics market could reach $18 billion¹ with up to six million addressable procedures annually, and gynecologic surgery representing about $1 billion in market potential, in the US alone.² Titan intends to initially pursue gynecologic surgical indications with the Enos system.
• The current robotic surgery market appears to be underpenetrated due in part to costs associated with existing robotic surgical systems. The Enos surgical system is being developed to allow hospitals to benefit from increased procedure throughput and reduced post-operative hospitalization of patients.
• Surgical procedures have evolved from open surgery with the growth of minimally invasive surgery, and further with the evolution in robotic assisted surgery. Current robotic assisted surgical systems are primarily comprised of multi-port systems, typically involving three instruments and a camera, and each requiring a separate incision. With single port, or single access, robotic surgery, the number and size of incisions, or access points, is further reduced. The Enos surgical system is a robotic surgical system designed for single access surgery.
• Reducing the number of incisions to a single access point may potentially reduce the trauma, complications, scarring, healing time, and use of post-operative pain medications associated with surgery. This may especially be relevant in the context of a post-COVID-19 environment.

Titan Medical’s Enos Surgical System:

• Through an aperture of approximately 25-millimeter diameter, the Enos robotic single access surgical system is designed to provide:
  • Two multi-articulating instruments with fluid “snake-like” movement engineered to generate the forces necessary for performing complex surgical tasks, including suturing, and built with an open architecture to accommodate a variety of end-effectors and to adapt to future surgical tools and technologies.
  • A dual-view 3D and 2D endoscopic high-definition vision system, each supporting independent integrated illumination.
• An easy to maneuver ergonomic surgeon workstation has been designed with embedded software for simulation training and surgeon overlays for providing interoperative feedback.
• A compact single-arm patient cart provides for fast set-up and unencumbered assistance by operating room staff.
• The complete surgical system of a surgeon workstation, patient cart, instrument and accessories is designed to deliver operating room efficiency and positive hospital economics.
• While the initial indication for use is expected to be benign gynecologic surgery, preclinical evidence suggests that the system may ultimately have application in other subspecialties, including urologic, colorectal and general surgery.⁴
• An expanding intellectual property portfolio presently comprises over 150 U.S. and international patents issued or pending. Titan’s intellectual property stems from several years of innovation in robotic assisted surgery covering technologies from hand controllers, to multi-articulating instruments, to unique software functionality including interoperative feedback. A select portion of the intellectual property portfolio and associated technologies have been licensed to global medical device leader Medtronic plc in exchange for license fees, with the Company retaining world-wide rights to commercialize the technologies for use with the Enos surgical system. The Company continues to build on and seek additional avenues for leveraging and/or expanding its intellectual property portfolio.

Corporate Resources:

• As of January 31, 2021, the Company had pro forma cash and cash equivalents of approximately $65.5 million when including proceeds of over $30 million in equity financings and $10 million in warrant exercises in January and February 2021.
• In 2020, the Company generated $20 million in license revenue from its development and license agreements with Medtronic.

Future Company Milestones:

• Under an ongoing development and license agreement with Medtronic and with the satisfaction of certain milestones thereunder, the Company expects to generate $21 million in additional license revenue in 2021.
• With its Enos surgical system, over the next two years the Company plans to complete product development and tooling for initial manufacturing, apply for an Investigational Device Exemption from the U.S. FDA, and once approve

FAQ

What is Titan Medical's TMDI surgical system?

Titan Medical's TMDI system, known as Enos™, focuses on robotic single access surgery aiming to minimize trauma and improve recovery for gynecologic procedures.

What is the market potential for Titan Medical's Enos system?

The U.S. surgical robotics market could reach $18 billion, with the gynecologic surgery segment representing about $1 billion.

What are Titan Medical's future plans for the Enos system?

Titan Medical plans to complete product development and human clinical studies for the Enos system in 2022.

How much cash does Titan Medical have?

As of January 31, 2021, Titan Medical reported approximately $65.5 million in cash and cash equivalents.

What revenue did Titan Medical generate in 2020?

Titan Medical generated $20 million in license revenue from its agreements with Medtronic in 2020.

What is the expected revenue from Medtronic in 2021?

Titan Medical expects to generate $21 million in additional license revenue from Medtronic in 2021.